Shield Therapeutics PLC represents values of innovation, integrity, and patient-centricity. With a strong focus on developing and commercializing pharmaceutical products, Shield Therapeutics is driven by the goal of addressing unmet medical needs for patients worldwide. The company is dedicated to delivering high-quality, evidence-based treatments that improve patients' lives. By promoting a culture of transparency, collaboration, and ethical conduct, Shield Therapeutics ensures that its stakeholders are at the heart of every decision and action. With a commitment to advancing healthcare solutions, Shield Therapeutics PLC strives to make a positive impact on the well-being of individuals and communities.

Shield Therapeutics PLC is primarily present in various countries and regions around the world. The company has a global presence and operates in multiple countries including the United Kingdom, Germany, France, Spain, Italy, and the United States. Shield Therapeutics PLC has established a strong international presence to expand its reach and cater to a diverse range of markets. With its extensive geographical coverage, Shield Therapeutics PLC is well-positioned to leverage opportunities and serve patients’ needs in different parts of the world.

Shield Therapeutics PLC has achieved significant milestones in its journey. The company successfully completed the pivotal Phase 3 clinical trials for its lead product, Feraccru®, a novel oral iron therapy for the treatment of iron deficiency anemia. Shield Therapeutics PLC received regulatory approval from the European Medicines Agency (EMA) for Feraccru® in 2016, allowing for its commercialization in Europe. The company also secured marketing authorizations in various European countries, including the UK, Germany, and Switzerland. These achievements highlight Shield Therapeutics PLC's commitment to addressing unmet medical needs and advancing innovative therapies in the field of iron deficiency anemia.

Shield Therapeutics PLC is a pharmaceutical company based in the United Kingdom. Founded in 2008, Shield Therapeutics focuses on the development and commercialization of products for the treatment of iron deficiency. The company is dedicated to addressing the unmet medical needs of patients suffering from iron deficiency-related conditions. Shield Therapeutics PLC aims to improve patient outcomes through its innovative and patient-centric approach to developing and delivering iron-based therapies. With a strong focus on research and development, Shield Therapeutics PLC is committed to advancing the field of iron deficiency treatment and improving the lives of patients worldwide.

The main competitors of Shield Therapeutics PLC in the market include pharmaceutical companies focusing on the development and commercialization of iron deficiency treatments. Some prominent competitors in this space are Ferrexpo PLC, AMAG Pharmaceuticals, Inc., and Vifor Pharma Ltd. These companies also aim to address iron deficiency conditions through innovative medical solutions and therapies. Shield Therapeutics PLC competes with these industry players to establish its presence and provide effective treatment options for patients affected by iron deficiency.

Shield Therapeutics PLC is primarily active in the pharmaceutical industry.

The business model of Shield Therapeutics PLC is focused on the development and commercialization of pharmaceutical products, particularly in the field of iron deficiency. Shield Therapeutics aims to offer innovative solutions to patients with iron deficiency, including those with chronic kidney disease. By focusing on this niche market, Shield Therapeutics strives to provide effective treatments and improve the quality of life for patients suffering from iron deficiency. Shield Therapeutics PLC is committed to research and development, ensuring the safety, efficacy, and accessibility of their pharmaceutical products.

Shield Therapeutics KGV ir -1,06.

Shield Therapeutics KUV ir 0,67.

AlleAktien kvalitātes vērtējums Shield Therapeutics ir 6/10.

gaidāmā Shield Therapeutics apgrozījums ir 28,78 milj. GBP.

gaidāmā Shield Therapeutics peļņa ir -18,05 milj. GBP.

Shield Therapeutics PLC is a British pharmaceutical company focused on the development and marketing of innovative drugs. The company specializes in the treatment of iron-deficiency anemia, which affects millions of people worldwide. The main focus of the company is the development of drugs for the treatment of iron-deficiency anemia in adults. They use a proprietary iron-based complex molecule called Ferric Maltol, which is able to transport and store iron more effectively and tolerably in the body compared to conventional iron supplements. The company's main product is Accrufer, an orally administered ferric iron supplement approved for the treatment of iron-deficiency anemia in adults. Accrufer has already proven to be effective and well tolerated in clinical studies and is now available on the market in several European countries, including Germany, the United Kingdom, Italy, and Spain. In addition to the development and marketing of Accrufer, Shield Therapeutics PLC also conducts research and development in the field of iron-based drugs. They collaborate closely with leading scientific institutions and research facilities to identify and develop new active substances. Furthermore, Shield Therapeutics PLC is involved in licensing and partnerships. The company aims to distribute its products worldwide and therefore works with various distribution partners and licensees to strengthen its global presence. Overall, the business model of Shield Therapeutics PLC is focused on providing effective and well-tolerated treatment for patients with iron-deficiency anemia. They pursue a holistic approach that includes research and development of new active substances as well as marketing and partnerships with other companies.

Shield Therapeutics izmaksā dividendes 0 GBP, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Shield Therapeutics vai uzņēmums nedod dividendes.

Shield Therapeutics ISIN ir GB00BYV81293.

Shield Therapeutics WKN ir A2AE98.

Shield Therapeutics simbols ir STX.L.

Pēdējo 12 mēnešu laikā Shield Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Shield Therapeutics plāno maksāt dividendes 0 GBP apmērā.

Shield Therapeutics pašreizējā dividendu rentabilitāte ir .

Shield Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Shield Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 GBP. Tas atbilst dividendes ražībai 0 %.

Shield Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Shield Therapeutics apmērā 0 GBP, kas tika izmaksāta 3.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 3.08.2024..

Pēdējās dividendes izmaksa notika 3.08.2024..

Gadā 2023, Shield Therapeutics izmaksāja 0 GBP dividendes.

Shield Therapeutics dividendes tiek izmaksātas GBP.